Overview

A Study in Patients With Advanced Cancers

Status:
Recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
A first-in-human study using TT-816 as a single agent and in combination with a PD-1 inhibitor in advanced cancers.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Teon Therapeutics, Inc.
Treatments:
Immune Checkpoint Inhibitors